CivaTech Oncology, an RTP medical device company dedicated to
developing novel radiation therapy devices, announced the award of a
$1M Phase II Contract from the National Institutes of Health and the
National Cancer Institute to further develop and commercialize CivaSheet TM,
a bioabsorbable uni-directional device for treatment of non-small-cell
lung cancer. This contract's objective is to meet regulatory
requirements that will enable the CivaSheet TM to be
introduced into clinical practice.
The Phase II Award
"We are extremely proud to be among the organizations selected to
receive a Phase II Contract," said Suzanne Babcock, Co-Founder and
Executive Chairman. "Our Company has dedicated itself to the mission of
improving cancer therapy with novel polymer-based radiation sources that
strive to maximize quality of life. We are very excited about the
recognition and support provided by the National Institutes of Health
and the National Cancer Institute and I would like to thank the members
of our team who worked with enthusiasm and perseverance to make this
possible."
In 2010, CivaTech Oncology received a Phase I Contract from the NIH to
begin development of this product. Mrs. Babcock indicated that CivaSheet
TM is a breakthrough technology for the treatment of
tumors where dose uniformity, bioabsorbability and a uni-directional
treatment are critical.
AI indelibly transforms solid tumor drug development